Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 17/20 | 0.64 |
| ▸ | CA2 | P00918 | 17/20 | 0.64 |
| ▸ | CA12 | O43570 | 5/20 | 0.64 |
| ▸ | CA9 | Q16790 | 5/20 | 0.64 |
| ▸ | CA4 | P22748 | 2/20 | 0.60 |
| ▸ | CA6 | P23280 | 2/20 | 0.60 |
| ▸ | CA5A | P35218 | 2/20 | 0.60 |
| ▸ | CA7 | P43166 | 2/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.60 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.60 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5684413 | 0.80 | CA1 (0.64) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL28696244 | 0.78 | CA2 (0.52) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1122831 | 0.78 | CA1 (0.61) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1644126 | 0.78 | CA1 (1.00) | CA1CA2CA12CA9CA6 | |
| SCHEMBL1645913 | 0.78 | CA1 (1.00) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL3041175 | 0.78 | CA1 (0.52) | CA1CA2CA12CA9CA4 | |
| SCHEMBL28750070 | 0.78 | CA1 (1.00) | CA1CA2CA12CA9CA4 | |
| SCHEMBL8519790 | 0.78 | CA1 (1.00) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL28472964 | 0.78 | CA2 (1.00) | CA1CA2CA12CA9CA4 | |
| SCHEMBL25547113 | 0.78 | CA2 (0.68) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849653-B2 | 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis | PHARMACIA CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1438293-A2 | SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030125361-A1 | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-07-03 | — | — | US | disclosed |
| WO-2003027075-A2 | SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125361-A1 | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation | IRAK4, NLRP3, CXCL8 | CA1 3893/4885CA2 4013/4885CA12 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.